Basic farmakokinetic properties of drugs used in multiple sclerosis Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Sep 30, 2016
Keywords:
drugs, multiple sclerosis, pharmacokinetics, pharmacodynamics, interactions

Main Article Content

Dagmara Mirowska-Guzel
1. Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej, Warszawski Uniwersytet Medyczny, Centrum Badań Przedklinicznych CePT. 2. II Klinika Neurologiczna, Instytut Psychiatrii i Neurologii w Warszawie
Joanna Przybek
Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej, Warszawski Uniwersytet Medyczny, Centrum Badań Przedklinicznych CePT

Abstract

Recent advancements in the therapy of multiple sclerosis have brought significant improvements in the course of the disease. Drugs that are currently available in Poland are: interferons, glatiramer acetate, dimethyl fumarate as a first-line therapy, fingolimod and natalizumab as asecond-line treatment. Addditionally teryflunomide and alemtuzumab has been also registered. All above drugs differs in route of administration, frequency of using, farmacodynamic and farmakokinetic properties, efficacy and safety profile. Newer drugs are considered to be more effective but they might also have higher risk of adverse effect. Drug-drug interactions might be also essential and even life-threatening however for majority of disease-modifying drugs used in multiple sclerosis they are not well known. This knowledge might be essential for optimizing multiple sclerosis therapy. This review is aimed at providing up to date data on these interactions as well as on pharmacokinetics.

Article Details

Issue
Vol 5 No 3(18) (2016)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. English C., Aloi J.J.: New FDA approved disease-modyfing therapies for multiple sclerosis. Clin. Ther. 2015; 37(4): 691-715.
2. Finkelsztejn A.: Multiple sclerosis: overview of disease-modyfing agents. Perspect. Medicin. Chem. 2014; 6: 65-72.
3. Farmakokinetyka. W: Farmakologia. Rang H.P., Dale M., Ritter J. (red.). Elsevier Urban i Partner, Wrocław 2014: 126-134.
4. Wchłanianie i dystrybucja leku. W: Farmakologia. Rang H.P., Dale M., Ritter J. (red.). Elsevier Urban i Partner, Wrocław 2014: 102-125.
5. Katzung B., Masters S., Trevor A.: Farmakologia ogólna i kliniczna. Czelej, Lublin 2012: 39-56.
6. Subramanian N., Condic-Jurkic K., O’Mara M.L.: Structural and dynamic perspectives on the promiscuous transport activity of P-glycoprotein. Neurochem. Int. 2016; 98(2): 146-152.
7. Jana S., Paliwal J.: Molecular mechanisms of cytochrome p450 induction: potential for drug-drug interactions. Curr. Protein. Pept. Sci. 2007; 8(6): 619-128.
8. Tang X., Chen S.: Epigenetic regulation of cytochrome P450 enzymes and clinical implication. Curr. Drug. Metab. 2015; 16(2): 86-96.
9. Gawrońska-Szklarz B., Białecka M., Droździk M.: Podstawowe pojęcia dotyczące przemian oraz działania leków w organizmie. W: Interakcje leków w neurologii. Białecka M., Sławek J. (red.). Via Medica, Gdańsk 2015: 1-13.
10. Sprouse A.A., van Breemen R.B.: Pharmacokinetic interactions between drugs and botanical dietary supplements. Drug. Metab. Dispos. 2016; 44(2):162-171.
11. Wang Z., Gorski J.C., Hamman M.A. et al.: The effect of St John’s wort (Hypericumperforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther. 2001; 70(4): 312-326.
12. Oga E.F., Sekine S., Shitara Y. et al.: Pharmacokinetic herb-drug interactions: insight into mechanisms and consequences. Eur. J. Drug. Metab. Pharmacokinet. 2016; 41(2): 93-108.
13. Obach R.S., Walsky R.L., Venkatakrishnan K. et al.: The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interaction. J. Pharmacol. Exp. Therap. 2006; 316(1): 336-348.
14. Lepist E.I., Ray A.S.: Renal transporter-mediated drug-drug interactions: are they clinically relevant? J. Clin. Pharmacol. 2016; 56(S7): 73-81.
15. Mirowska-Guzel D., Członkowska A.: Leki stosowane w stwardnieniu rozsianym. W: Interakcje leków w neurologii. Białecka M., Sławek J. (red.). Via Medica, Gdańsk, 2015: 277-302.
16. Clanet M.C., Wolinsky J.S., Ashton R.J. et al.: Risk evaluation and monitoring in multiple sclerosis therapeutics. Mult. Scler. J. 2014; 20(10): 1306-1311.
17. Charakterystyka Produktu Leczniczego. Avonex [online].
18. Charakterystyka Produktu Leczniczego. Extavia [online].
19. Charakterystyka Produktu Leczniczego. Betaferon [online].
20. Charakterystyka Produktu Leczniczego. Rebif [online].
21. Charakterystyka Produktu Leczniczego. Plegridy [online].
22.Charakterystyka Produktu Leczniczego. Octan glatirameru [online].
23. Borchardt J., Berger J.M.: Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy. Mult. Scler. Relat. Disord. 2016; 8: 145-150.
24. Charakterystyka Produktu Leczniczego. Natalizumab [online].
25. Bezabeh S., Flowers C.M., Kortepeter C. et al.: Clinically significant liver injury in patients treated with natalizumab. Aliment. Pharmacol. Ther. 2010; 31: 1028-1035.
26. Charakterystyka Produktu Leczniczego. Fingolimod [online].
27. Charakterystyka Produktu Leczniczego. Dimetyl fumaranu [online].
28. Charakterystyka Produktu Leczniczego. Teryflunomid [online].
29. Charakterystyka Produktu Leczniczego. Alemtuzumab [online].